DOP2009000055A - NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT - Google Patents

NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT

Info

Publication number
DOP2009000055A
DOP2009000055A DO2009000055A DO2009000055A DOP2009000055A DO P2009000055 A DOP2009000055 A DO P2009000055A DO 2009000055 A DO2009000055 A DO 2009000055A DO 2009000055 A DO2009000055 A DO 2009000055A DO P2009000055 A DOP2009000055 A DO P2009000055A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
cytotoxic
conjugates
treatment
fragments
Prior art date
Application number
DO2009000055A
Other languages
Spanish (es)
Inventor
Peter U Park
Laura M Bartle
Anna Skaletskaya
Daniel Tavares
Jutta Deckert
Vincent Mikol
Veronique Blanc
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Priority to DO2009000055A priority Critical patent/DOP2009000055A/en
Publication of DOP2009000055A publication Critical patent/DOP2009000055A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos, anticuerpos humanizados, anticuerpos con supeficie modificada, fragmentos de anticuerpo, anticuerpos derivatizados, y conjugados de los mismos con agentes citotóxicos, que se unen especificamente a CDC38, son capaces de destruir las células CD38+ por apoptosis, citotoxicidad mediada por las células dependiente del anticuerpo (ADCC), y/o citotoxicidad dependiente del complemento (ACDC). Dichos anticuerpos y fragmentos de los mismos se pueden usar en el tratamiento de tumores que expresan niveles elevsados de proteína CD38, tales como mieloma múltiple, leucemia linfocitica crónica, leucemia mielógena crónica , leucemia mielógena aguda, o leucemia linfocitica aguda, o en el tratamiento de enfermedades autoinmunes e inflamatorias tales como lupus eritematoso sistématico, artritis reumatoide, esclerosis múltiple y asma. Dichos anticuerpos derivatizados se pueden usar en la diagnosis y diagnóstico por imagen de tumores que expresan niveles elevados de CD38. Tambien se proporcionan conjugados citotóxicos que comprenden un agente de unión a las células y un agente citotóxico, composiciones terapéuticas que comprenden el conjugado, métodos para usar los conjugados en la inhibición del crecimiento celular y en el tratamiento de la enfermedad, y un kit que comprende el conjugado citotóxico. En particular, el agente de unión a las células es un anticuerpo monoclonal, y los fragmjentos de éste que se unen al epítolo, que reconoce y se une a la proteína CD38.Antibodies, humanized antibodies, modified surface antibodies, antibody fragments, derivatized antibodies, and conjugates thereof with cytotoxic agents, which specifically bind to CDC38, are capable of destroying CD38 + cells by apoptosis, cell-mediated cytotoxicity dependent on antibody (ADCC), and / or complement dependent cytotoxicity (ACDC). Such antibodies and fragments thereof can be used in the treatment of tumors expressing elevated levels of CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or in the treatment of autoimmune and inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and asthma. Such derivatized antibodies can be used in the diagnosis and diagnostic imaging of tumors expressing elevated levels of CD38. Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and in the treatment of the disease, and a kit comprising are also provided. the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and the fragments thereof that bind to the epitolus, which recognizes and binds to the CD38 protein.

DO2009000055A 2009-03-30 2009-03-30 NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT DOP2009000055A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DO2009000055A DOP2009000055A (en) 2009-03-30 2009-03-30 NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DO2009000055A DOP2009000055A (en) 2009-03-30 2009-03-30 NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT

Publications (1)

Publication Number Publication Date
DOP2009000055A true DOP2009000055A (en) 2009-06-30

Family

ID=44261559

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000055A DOP2009000055A (en) 2009-03-30 2009-03-30 NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT

Country Status (1)

Country Link
DO (1) DOP2009000055A (en)

Similar Documents

Publication Publication Date Title
AR063488A1 (en) NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT
CO2017010495A2 (en) Antibodies that bind bcma and / or cd3
ECSP099074A (en) ANTAGONIST ANTIBODY FOR CANCER TREATMENT
ES2571235T3 (en) Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
BR112018005573A2 (en) "cd3 binding polypeptides"
UY36289A (en) MONOCLONAL ANTIBODIES THAT IMMUNE SPECIFICALLY LINK TO CD123 and COMPOSITIONS THAT CONTAIN THEM
EA201171374A1 (en) ANTIBODIES AGAINST CD100 AND METHODS OF THEIR APPLICATION
AR078470A1 (en) ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
BR112013005145A2 (en) anti-cxcl13 antibodies and methods for their use
MX369148B (en) Kir3dl2 binding agents.
EA201490957A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY
PE20161327A1 (en) BINDING PROTEINS TO THE HUMAN IL-23 ANTIGEN
MX2010010387A (en) Bcr-complex-specific antibodies and methods of using same.
CO2018004930A2 (en) Specific binding molecules for asct2
BR112014029089A2 (en) antibody or antigen binding fragment thereof; polynucleotide encoding; compound; pharmaceutical composition / formulation; kit; use; in vitro method for reducing or inhibiting tg2 enzyme activity
CO6630177A2 (en) Compositions and methods for the diagnosis and treatment of tumors
DOP2009000055A (en) NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT
PE20091406A1 (en) CANCER DISEASE MODIFYING ANTIBODIES
AR122052A2 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
AR106658A1 (en) ASCT2 SPECIFIC UNION MOLECULES AND THEIR USES
PE20091365A1 (en) CANCER DISEASE MODIFYING ANTIBODIES
TH134910B (en) Anti-CD 100 antibodies (Anti-CD100 ANTIBODIES) and method for the same application.
AR071847A1 (en) MONOCLONAL ANTIBODIES MODIFYING CANCER DISEASES
AR068664A1 (en) HUMANIZED MONOTIONAL ANTIBODIES CANCEROSE DISEASE MODIFIER (CDMAB) AND ITS USE, FOR CANCER DIAGNOSIS AND TREATMENT
PE20091437A1 (en) CANCER DISEASE MODIFYING ANTIBODIES